China Merchants Bank International and Mirae Asset Financial Group led a USD120m Series C for EpimAb Biotherapeutics, a China-based developer of bispecific antibodies, with participation from Hony Capital, Cormorant Asset Management, Yanchuang Capital, Octagon Capital, ShangBay Capital and Adrian Cheng (New World Development) and follow-on from Decheng Capital, SDIC Fund Management, Sherpa Healthcare Partners and Hidragon Capital. Read more